TCTeresa Caiazzo

Teresa Caiazzo

*This is an algorithmically generated author record based on publicly available information.

Teresa Caiazzo has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Competitive Ligand-Binding Assay to Detect Neutralizing Antibodies to a Bispecific Drug Using a Multiplex Meso Scale Discovery Platform

    by Vitaly Ablamunits, Soma Basak, Rosemary Lawrence-Henderson, Teresa M Caiazzo, John Kamerud

    Background: Monitoring appearance of neutralizing antibodies (NAbs) to multidomain large molecule drugs is a challenging task. Materials & methods: Here, we report development of a competitive liga...


  • Open Access

    Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy

    by Vahid Farrokhi, Jason Walsh, Joe Palandra, Joanne Brodfuehrer, Teresa Caiazzo, Jane Owens, Michael Binks, Srividya Neelakantan, Florence Yong, Pinky Dua, et al.

    Duchenne muscular dystrophy (DMD) is a lethal, degenerative muscle disorder caused by mutations in the DMD gene, leading to severe reduction or absence of the protein dystrophin. Gene therapy strategies that aim to increase expression of a functional dystrophin protein (mini-dystrophin) are under investigation. The ability to accurately quantify dystrophin/mini-dystrophin is essential in assessing the level of gene transduction. We demonstrated the validation and application of a novel peptide immunoaffinity liquid chromatography–tandem mass spectrometry (IA-LC-MS/MS) assay. Data showed that dystrophin expression in Becker muscular dystrophy and DMD tissues, normalized against the mean of non-dystrophic control tissues (n = 20), was 4–84.5% (mean 32%, n = 20) and 0.4–24.1% (mean 5%, n = 20), respectively. In a DMD rat model, biceps femoris tissue from dystrophin-deficient rats treated with AAV9.hCK.Hopti-Dys3978.spA, an adeno-associated virus vector containing a mini-dystrophin transgene, showed a dose-dependent increase in mini-dystrophin expression at 6 months post-dose, exceeding wildtype dystrophin levels at high doses. Validation data showed that inter- and intra-assay precision were ≤20% (≤25% at the lower limit of quantification [LLOQ]) and inter- and intra-run relative error was within ±20% (±25% at LLOQ). IA-LC-MS/MS accurately quantifies dystrophin/mini-dystrophin in human and preclinical species with sufficient sensitivity for immediate application in preclinical/clinical trials.


  • Critical Reagent Characterization and Re-Evaluation to Ensure Long-Term Stability: Two Case Studies

    by Teresa M Caiazzo, Christopher M Shea, Alison P Joyce

    Characterization of critical reagents can mitigate adverse impact to ligand-binding assay performance. We investigated the conjugation conditions of a bispecific protein to SULFO-TAG NHS-Ester™ rut...


  • Open Access

    Human FcRn Tissue Expression Profile and Half-Life in PBMCs

    by Yao-Yun Fan, Vahid Farrokhi, Teresa Caiazzo, Mengmeng Wang, Denise M. O’hara, Hendrik Neubert

    System-wide quantitative characterization of human neonatal Fc receptor (FcRn) properties is critical for understanding and predicting human PK (pharmacokinetics) as well as the distribution of mAbs and Fc-fusion proteins using PBPK (physiologically-based pharmacokinetic) modeling. To this end, tissue-specific FcRn expression and half-life are important model inputs. Herein, human FcRn tissue expression was measured by peptide immunoaffinity chromatography coupled with high-resolution mass spectrometry. FcRn concentrations across 14 human tissues ranged from low to 230 pmol per gram of tissue. Furthermore, the FcRn half-life was determined to be 11.1 h from a human stable isotope labelled leucine pulse labeling experiment. The spatial and temporal quantitative human FcRn data now promise to enable a refined PBPK model with improved accuracy of human PK predictions for Fc-containing biotherapeutics.